Can persistent nerve injury activate phospholipase pathways and lipid mediators that sustain pain?

Persistent nerve injury can engage lipid-inflammatory signaling that is biologically well positioned to amplify nociception. The overall pathway is strongly grounded biochemically and in experimental neuropathic-pain models, but its role as a sustained driver in established human neuropathic conditions remains incompletely demonstrated.

Mechanistic evidence

• Peripheral nerve injury increases phospholipase A₂ (PLA₂), including cytosolic PLA₂, activity in dorsal-root-ganglion and spinal neuroimmune compartments. PLA₂ hydrolyzes membrane phospholipids to release arachidonic acid.
• Arachidonic acid is then metabolized through cyclooxygenase pathways to prostaglandins (including PGE₂ and PGI₂), or through 5-lipoxygenase (5-LOX) to leukotrienes. In injury models, arachidonic-acid-containing phosphatidylcholine accumulates in injured spinal tissue alongside reactive microglia and astrocytes.
• Spinal microglia express 5-LOX; microglia-derived LTB₄ can activate neuronal BLT1 receptors, enhance NMDA-receptor currents, and promote central sensitization.

Pain and neuroinflammatory implications

• PGE₂ can sensitize TRPV1, voltage-gated sodium and calcium channels, and P2X3 receptors, increasing nociceptor excitability and supporting allodynia in preclinical models.
• 5-LOX inhibition or leukotriene-receptor antagonism reduces mechanical allodynia in rodents. Leukotriene antagonism also reduces glial activation and cytokine production, supporting a neuroinflammatory role.
• Inflammatory signaling as an independent upstream trigger of PLA₂ is mechanistically plausible, but has not been cleanly separated from concurrent nerve-injury neuronal and glial signaling.

Clinical implications

• These findings support eicosanoid pathways as potential amplifiers of persistent pain rather than proving they are universal causes of chronic neuropathic pain. Human evidence—including for postherpetic neuralgia—is limited, and no convincing randomized evidence currently supports routine selective EP, 5-LOX, or leukotriene-receptor targeting.

Bottom line

• The claim is biologically credible and well supported in animal and mechanistic research; translation to established human chronic pain and neuroinflammation remains unproven.